Literature DB >> 16082216

Death-from-cancer signatures and stem cell contribution to metastatic cancer.

Gennadi V Glinsky1.   

Abstract

Genome-wide expression profiling studies reveal a transcriptionally distinct sub-type of human solid tumors with a marked propensity toward metastatic dissemination, highly malignant clinical behavior, and poor therapy outcome in cancer patients diagnosed with the early stage carcinomas of various origins. This sub-set of tumors acquires full metastatic potential, including an emergence and seeding of potent metastasis precursor cells, early in tumor progression. Collectively, these data suggest an early involvement in development of this transcriptionally defined sub-type of human carcinomas of a highly malignant combination of mutant alleles conferring the proclivity to metastasize and/or an engagement in transformation and tumor progression of stem cells and/or early progenitor cells. Enrichment of primary tumors with normal stem cells increases the likelihood of horizontal genomic transfer (large-scale transfer of DNA and chromatin) between stem cells and cancer cells via cell fusion and/or uptake of apoptotic bodies and generation of reprogrammed somatic cell hybrids with self-renewing highly malignant phenotype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16082216     DOI: 10.4161/cc.4.9.2001

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  47 in total

1.  Fabrication and biological evaluation of uniform extracellular matrix coatings on discontinuous photolithography generated micropallet arrays.

Authors:  Nicholas M Gunn; Mark Bachman; Guann-Pyng Li; Edward L Nelson
Journal:  J Biomed Mater Res A       Date:  2010-11       Impact factor: 4.396

2.  Stem cells: promises and realities in cancer research.

Authors:  D García-Olmo; D C García-Olmo
Journal:  Clin Transl Oncol       Date:  2006-05       Impact factor: 3.405

3.  p38 mitogen-activated protein kinase inhibits USP22 transcription in HeLa cells.

Authors:  Jianjun Xiong; Zhen Gong; Xiaou Zhou; Jianyun Liu; H E Jiang; Ping Wu; Weidong Li
Journal:  Biomed Rep       Date:  2015-04-16

Review 4.  The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.

Authors:  T F Sumter; L Xian; T Huso; M Koo; Y-T Chang; T N Almasri; L Chia; C Inglis; D Reid; L M S Resar
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

Review 5.  Aurora B hyperactivation by Bub1 overexpression promotes chromosome missegregation.

Authors:  Robin M Ricke; Jan M van Deursen
Journal:  Cell Cycle       Date:  2011-11-01       Impact factor: 4.534

6.  The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors.

Authors:  Prashant V Bommi; Manjari Dimri; Anagh A Sahasrabuddhe; Janardan Khandekar; Goberdhan P Dimri
Journal:  Cell Cycle       Date:  2010-07-01       Impact factor: 4.534

7.  ShRNA-mediated silencing of the ubiquitin-specific protease 22 gene restrained cell progression and affected the Akt pathway in nasopharyngeal carcinoma.

Authors:  Ya-Jing Zhuang; Zhi-Wei Liao; Hong-Wei Yu; Xian-Lu Song; Yuan Liu; Xing-Yuan Shi; Xiao-Dan Lin; Tong-Chong Zhou
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

8.  The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression.

Authors:  Xiao-Yong Zhang; Maya Varthi; Stephen M Sykes; Charles Phillips; Claude Warzecha; Wenting Zhu; Anastasia Wyce; Alan W Thorne; Shelley L Berger; Steven B McMahon
Journal:  Mol Cell       Date:  2008-01-18       Impact factor: 17.970

9.  Deletion analysis of BMI1 oncoprotein identifies its negative regulatory domain.

Authors:  Ajay K Yadav; Anagh A Sahasrabuddhe; Manjari Dimri; Prashant V Bommi; Rachana Sainger; Goberdhan P Dimri
Journal:  Mol Cancer       Date:  2010-06-22       Impact factor: 27.401

10.  BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases.

Authors:  M J Hoenerhoff; I Chu; D Barkan; Z-y Liu; S Datta; G P Dimri; J E Green
Journal:  Oncogene       Date:  2009-06-22       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.